Vivesto AB
OMAX
Company Profile
Business description
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
Contact
Gustav III:s Boulevard 46
5th Floor
SolnaSE-169 73
SWET: +46 18505440
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
stocks
Most popular shares in SMSFs
With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,208.50 | 9.00 | -0.10% |
| CAC 40 | 7,898.18 | 36.08 | -0.45% |
| DAX 40 | 24,142.95 | 244.98 | -1.00% |
| Dow JONES (US) | 45,534.48 | 533.10 | -1.16% |
| FTSE 100 | 9,423.51 | 19.36 | -0.21% |
| HKSE | 25,441.35 | 448.13 | -1.73% |
| NASDAQ | 22,278.76 | 415.85 | -1.83% |
| Nikkei 225 | 46,847.32 | 1,733.12 | -3.57% |
| NZX 50 Index | 13,276.99 | 74.93 | -0.56% |
| S&P 500 | 6,570.22 | 84.50 | -1.27% |
| S&P/ASX 200 | 8,899.40 | 10.30 | -0.12% |
| SSE Composite Index | 3,865.23 | 24.27 | -0.62% |